Garcinol sensitizes human head and neck carcinoma to cisplatin in a xenograft mouse model despite downregulation of proliferative biomarkers

• المؤلفون الرئيسيون: Li F., Shanmugam M.K., Siveen K.S., Wang F., Ong T.H., Loo S.Y., Swamy M.M.M., Mandal S., Kumar A.P., Goh B.C., Kundu T., Ahn K.S., Wang L.Z., Hui K.M., Sethi G.
• مؤلفون آخرون: PHARMACOLOGY
• التنسيق: مقال
• منشور في: 2020
• الموضوعات: antineoplastic agent; benzophenone derivative; cisplatin; cyclin D1; garcinol; immunoglobulin enhancer binding protein; Ki 67 antigen; protein bcl 2; survivin; tumor marker; unclassified drug; vasculotropin; biological marker; messenger RNA; plant extract; terpene; animal cell; animal experiment; animal model; animal tissue; apoptosis; area under the curve; Article; cancer combination chemotherapy; cancer inhibition; cancer model; capillary density; carcinoma cell; cell viability; chemosensitization; controlled study; down regulation; drug absorption; drug blood level; drug exposure; drug potentiation; female; gene expression regulation; gene product; head and neck carcinoma; histopathology; human; human cell; in vivo study; maximum plasma concentration; monotherapy; mouse; nonhuman; systemic therapy; transcription initiation; tumor xenograft; \garcinol; animal; Carcinoma, Squamous Cell; cell proliferation; drug effects; drug screening; enzyme immunoassay; genetics; Head and Neck Neoplasms; metabolism; nude mouse; pathology; real time polymerase chain reaction; reverse transcription polymerase chain reaction; signal transduction; tumor cell culture; Western blotting; Animals; Antineoplastic Agents; Apoptosis; Biomarkers; Blotting, Western; Cell Proliferation; Cisplatin; Down-Regulation; Drug Synergism; Female; Humans; Immunoenzyme Techniques; Mice; Mice, Nude; Plant Extracts; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Terpenes; Tumor Cells, Cultured; Xenograft Model Antitumor Assays
• الوصول للمادة أونلاين: https://scholarbank.nus.edu.sg/handle/10635/174150

10.18632/oncotarget.2881